ERBB2 and choreatic disease: After injection of 1000 μg, the uptake (SUV max) of 99mTc-ZHER2:41071 in HER2-positive primary tumors (16.9 ± 7.6) 2 h after injection was on the same level or higher than the average uptake in HER2-positive primary breast cancer reported in clinical studies concerning other HER2-targeting Affibody molecules: 68Ga-NOTA-MAL-Cys-MZHER2:342 (2.16 ± 0.2) 17, 18F-AlF-NOTA-HER2-BCH (6.7 ± 4.3) and 18F-AlF-RESCA-HER2-BCH (7.8 ± 5.5) 20.